Traferox Technologies

Traferox Technologies is a biotechnology company focused on developing next-generation iron chelators for the treatment of iron overload disorders. The company's lead research is centered on creating orally bioavailable, highly selective small molecules that can effectively remove excess iron from the body with improved safety profiles compared to current standards of care. By targeting conditions such as transfusion-dependent thalassemia and sickle cell disease, Traferox aims to reduce the systemic toxicity and organ damage associated with chronic iron accumulation. The company is currently advancing its lead candidates through pre-clinical development to address significant unmet needs in hematology.